

**Rotblatt, Hart**

---

**From:** Melinda Hurley <MHurley@Sarepta.com>  
**Sent:** Monday, December 16, 2019 11:55 AM  
**To:** AGO - High Cost Prescription Drugs  
**Subject:** Notice of New Drug Introduction Pursuant to 18 V.S.A § 4637

**EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.**

**Date:** 12/16/2019

**To:** Office of Attorney General  
AGO.highcostprescriptiondrugs@vermont.gov

**From:** Sarapta Therapeutics  
215 First Street  
Cambridge, MA 02142

**Re:** Notice of New Drug Introduction Pursuant to 18 V.S.A. § 4637

---

To Whom It May Concern:

Sarapta Therapeutics submits this information pursuant to 18 V.S.A. § 4637.

NDC	Name of New Prescription Drug	Date of Commercial Availability	WAC
60923-465-02	VYONDYS 53 Golodirsen 100MG/2ML Injection vial in carton	12/12/2019	\$ 1,600.00

Sarapta reserves any and all rights that it may have to challenge the governing statute, its interpretation, or its application to Sarapta

Please reply to confirm receipt.

Sincerely,  
Melinda

**Melinda L. Hurley**  
Manager, Accounting

Sarepta Therapeutics  
215 First Street, Cambridge MA 02142  
d: 617.274.4020 m:617.999.7192  
e: [mhurley@sarepta.com](mailto:mhurley@sarepta.com)



---

The information contained in this message may be confidential, privileged and protected from disclosure. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by email or telephone and destroy all copies of the original message. Thank you.